phrykt

INSMED Inc (INSM): who owns it and who trades it

As of Nov 16, 2026, INSM insiders reported 152 open-market sales worth $148M and no purchases in the last 12 months, with 56% of the sale value made under pre-set 10b5-1 plans. The largest seller was Roger Adsett (Chief Operating Officer), with $48.3M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling INSMED

From the latest filings

Overall: more selling than buying. Insiders, famous investors and Congress mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns INSM

662 funds and institutions reported INSM shares worth $23.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 7.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)7.4%
BlackRock, Inc.7.3%
JPMorgan Chase & Co4.8%
Vanguard Portfolio Management LLC4.8%
Vanguard Capital Management LLC4.5%
Baker Bros. Advisors LP4.1%
Capital International Investors3.8%
Darwin Global Management, Ltd.3.0%
Ameriprise Financial Inc2.9%
Orbis Allan Gray Ltd2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)16.14M7.45%$1.7B+23%
BlackRock, Inc.15.81M7.29%$1.7B-5%
JPMorgan Chase & Co10.43M4.81%$1.1B–
Vanguard Portfolio Management LLC10.41M4.80%$1.1B+0%
Vanguard Capital Management LLC9.79M4.52%$1B+2%
Baker Bros. Advisors LP8.80M4.06%$938M+19%
Capital International Investors8.24M3.80%$878M+47%
Darwin Global Management, Ltd.6.43M2.97%$674M-62%
Ameriprise Financial Inc6.18M2.85%$659M+102%
Orbis Allan Gray Ltd6.08M2.80%$648M+224%
State Street Corp6.05M2.79%$645M+9%
D. E. Shaw & Co., Inc.5.88M2.71%$627M+4%
Artisan Partners Limited Partnership5.44M2.51%$580M-17%
Rtw Investments, LP4.84M2.23%$516MNo change
Geode Capital Management, LLC4.22M1.95%$449M-5%
T. Rowe Price Associates3.41M1.57%$363M+10%
Norges Bank3.38M1.56%$360M–
Jupiter Topco LLC2.61M1.20%$278M–
UBS Group AG2.58M1.19%$276M+49%
Citadel Advisors LLC2.56M1.18%$273M+17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, INSM insiders reported $0 of open-market purchases and $148M of sales. 56% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$148M
152 trades, 10 people
Sales under a 10b5-1 plan
56%
Share of sale value
Latest trade
Sep 9, 2026
Filed Sep 11, 2026

Purchases and sales by month

$36.1M$36.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 9, 2026David R BrennanDirectorSale25,000$124.00$3.1MForm 4
Aug 17, 2026Melvin Md SharokyDirectorSale5,000$127.53$638KForm 4
Aug 10, 2026Roger AdsettChief Operating OfficerSale239,850$133.27$32MForm 4
Aug 6, 2026Martina M.D. FlammerChief Medical OfficerSale plan8,895$127.00$1.1MForm 4
Aug 6, 2026Martina M.D. FlammerChief Medical OfficerSale plan18,278$129.40$2.4MForm 4
Jul 23, 2026William LewisCEOSale plan4,828$105.62$510KForm 4
Jul 23, 2026William LewisCEOSale plan5,872$106.43$625KForm 4
Jul 9, 2026William LewisCEOSale plan2,335$117.62$275KForm 4
Jul 9, 2026William LewisCEOSale plan3,359$118.52$398KForm 4
Jul 9, 2026William LewisCEOSale plan5,005$116.55$583KForm 4
Jul 6, 2026Martina M.D. FlammerChief Medical OfficerSale plan7,448$110.60$824KForm 4
Jul 6, 2026Martina M.D. FlammerChief Medical OfficerSale plan4,854$109.02$529KForm 4
Jun 25, 2026William LewisCEOSale plan1,292$106.27$137KForm 4
Jun 25, 2026William LewisCEOSale plan2,456$105.27$259KForm 4
Jun 25, 2026William LewisCEOSale plan3,723$104.28$388KForm 4
Jun 25, 2026William LewisCEOSale plan1,836$103.10$189KForm 4
Jun 25, 2026William LewisCEOSale plan12,091$102.34$1.2MForm 4
Jun 22, 2026Michael Alexander SmithChief Legal OfficerSale plan1,806$95.82$173KForm 4
Jun 8, 2026William LewisCEOSale plan6,515$94.03$613KForm 4
Jun 5, 2026Martina M.D. FlammerChief Medical OfficerSale plan1,858$103.78$193KForm 4
Jun 3, 2026Roger AdsettChief Operating OfficerSale2,370$102.27$242KForm 4
Jun 3, 2026Sara BonsteinCFOSale2,404$102.27$246KForm 4
Jun 3, 2026Michael Alexander SmithChief Legal OfficerSale2,159$102.27$221KForm 4
Jun 3, 2026William LewisCEOSale7,605$102.27$778KForm 4
Jun 3, 2026Martina M.D. FlammerChief Medical OfficerSale plan2,566$102.27$262KForm 4
May 22, 2026Michael Alexander SmithChief Legal OfficerSale plan6,149$108.47$667KForm 4
May 18, 2026William LewisCEOSale plan7,975$106.97$853KForm 4
May 18, 2026William LewisCEOSale plan5,753$105.32$606KForm 4
May 18, 2026William LewisCEOSale plan11,836$106.39$1.3MForm 4
May 14, 2026Martina M.D. FlammerChief Medical OfficerSale plan10,479$117.54$1.2MForm 4
May 13, 2026Sara BonsteinCFOSale8,272$116.18$961KForm 4
May 13, 2026Roger AdsettChief Operating OfficerSale5,837$116.18$678KForm 4
May 13, 2026Martina M.D. FlammerChief Medical OfficerSale plan4,470$112.76$504KForm 4
May 13, 2026Martina M.D. FlammerChief Medical OfficerSale plan3,384$116.18$393KForm 4
May 13, 2026Michael Alexander SmithChief Legal OfficerSale4,109$116.18$477KForm 4
May 13, 2026William LewisCEOSale13,283$116.18$1.5MForm 4
May 11, 2026Martina M.D. FlammerChief Medical OfficerSale plan12,119$100.35$1.2MForm 4
May 11, 2026Martina M.D. FlammerChief Medical OfficerSale plan830$101.18$84KForm 4
May 4, 2026William LewisCEOSale plan433$134.18$58.1KForm 4
May 4, 2026William LewisCEOSale plan381$139.60$53.2KForm 4
May 4, 2026William LewisCEOSale plan5,318$137.01$729KForm 4
May 4, 2026William LewisCEOSale plan2,721$137.86$375KForm 4
May 4, 2026William LewisCEOSale plan1,247$139.09$173KForm 4
May 4, 2026William LewisCEOSale plan599$135.18$81KForm 4
Apr 16, 2026William LewisCEOSale plan2,246$142.99$321KForm 4
Apr 16, 2026William LewisCEOSale plan5,373$143.81$773KForm 4
Apr 16, 2026William LewisCEOSale plan2,255$144.66$326KForm 4
Apr 16, 2026William LewisCEOSale plan825$145.79$120KForm 4
Apr 6, 2026William LewisCEOSale plan8,478$163.23$1.4MForm 4
Apr 6, 2026William LewisCEOSale plan787$161.73$127KForm 4
Apr 6, 2026William LewisCEOSale plan1,434$164.01$235KForm 4
Apr 1, 2026Roger AdsettChief Operating OfficerSale plan6,715$163.18$1.1MForm 4
Apr 1, 2026Roger AdsettChief Operating OfficerSale plan62,344$164.95$10.3MForm 4
Apr 1, 2026Roger AdsettChief Operating OfficerSale plan19,001$164.11$3.1MForm 4
Mar 30, 2026Michael Alexander SmithChief Legal OfficerSale plan19,638$150.98$3MForm 4
Mar 19, 2026William LewisCEOSale plan1,629$142.17$232KForm 4
Mar 19, 2026William LewisCEOSale plan4,537$143.42$651KForm 4
Mar 19, 2026William LewisCEOSale plan4,533$144.11$653KForm 4
Mar 5, 2026William LewisCEOSale plan2,128$147.54$314KForm 4
Mar 5, 2026William LewisCEOSale plan2,083$144.23$300KForm 4
Mar 5, 2026William LewisCEOSale plan2,589$145.27$376KForm 4
Mar 5, 2026William LewisCEOSale plan3,899$146.66$572KForm 4
Feb 24, 2026Michael Alexander SmithChief Legal OfficerSale plan4,852$153.93$747KForm 4
Feb 24, 2026Michael Alexander SmithChief Legal OfficerSale plan4,151$155.06$644KForm 4
Feb 24, 2026Michael Alexander SmithChief Legal OfficerSale plan15,771$156.53$2.5MForm 4
Feb 19, 2026William LewisCEOSale plan1,030$153.38$158KForm 4
Feb 19, 2026William LewisCEOSale plan3,413$151.12$516KForm 4
Feb 19, 2026William LewisCEOSale plan1,891$150.10$284KForm 4
Feb 19, 2026William LewisCEOSale plan1,988$149.17$297KForm 4
Feb 19, 2026William LewisCEOSale plan2,377$151.92$361KForm 4
Feb 9, 2026William LewisCEOSale plan1,287$148.83$192KForm 4
Feb 9, 2026William LewisCEOSale plan4,888$147.17$719KForm 4
Feb 9, 2026William LewisCEOSale plan7,221$148.02$1.1MForm 4
Feb 5, 2026Martina M.D. FlammerChief Medical OfficerSale plan869$152.44$132KForm 4
Feb 3, 2026Roger AdsettChief Operating OfficerSale791$156.17$124KForm 4
Feb 3, 2026Sara BonsteinCFOSale748$156.34$117KForm 4
Feb 3, 2026William LewisCEOSale3,009$156.34$470KForm 4
Feb 3, 2026Michael Alexander SmithChief Legal OfficerSale640$156.27$100KForm 4
Feb 3, 2026Martina M.D. FlammerChief Medical OfficerSale plan795$155.77$124KForm 4
Feb 2, 2026Martina M.D. FlammerChief Medical OfficerSale plan100$156.86$15.7KForm 4
Feb 2, 2026Martina M.D. FlammerChief Medical OfficerSale plan3,042$155.46$473KForm 4
Feb 2, 2026Martina M.D. FlammerChief Medical OfficerSale plan3,349$154.56$518KForm 4
Feb 2, 2026Martina M.D. FlammerChief Medical OfficerSale plan928$153.16$142KForm 4
Feb 2, 2026Martina M.D. FlammerChief Medical OfficerSale plan563$152.06$85.6KForm 4
Jan 20, 2026William LewisCEOSale plan1,006$156.80$158KForm 4
Jan 20, 2026William LewisCEOSale plan254$160.70$40.8KForm 4
Jan 20, 2026William LewisCEOSale plan1,243$158.37$197KForm 4
Jan 20, 2026William LewisCEOSale plan5,967$158.99$949KForm 4
Jan 20, 2026William LewisCEOSale plan2,229$159.85$356KForm 4
Jan 12, 2026William LewisCEOSale plan7,176$168.63$1.2MForm 4
Jan 12, 2026William LewisCEOSale plan6,996$169.57$1.2MForm 4
Jan 12, 2026William LewisCEOSale plan297$171.31$50.9KForm 4
Jan 12, 2026William LewisCEOSale plan297$172.36$51.2KForm 4
Jan 12, 2026William LewisCEOSale plan315$174.86$55.1KForm 4
Jan 12, 2026William LewisCEOSale plan3,974$167.73$667KForm 4
Jan 12, 2026William LewisCEOSale plan160$170.24$27.2KForm 4
Jan 9, 2026Martina M.D. FlammerChief Medical OfficerSale plan1,887$186.19$351KForm 4
Jan 8, 2026Roger AdsettChief Operating OfficerSale2,059$174.17$359KForm 4
Jan 8, 2026Sara BonsteinCFOSale1,447$174.17$252KForm 4
Jan 8, 2026Martina M.D. FlammerChief Medical OfficerSale plan3,251$174.17$566KForm 4

Latest 100 of 152 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Roger AdsettChief Operating Officer–$48.3MAug 10, 2026
William LewisChair and CEO, Director–$32.8MJul 23, 2026
Martina M.D. FlammerChief Medical Officer–$17.4MAug 6, 2026
Orlov S Nicole SchaefferChief People Strategy Officer–$15.3MJan 2, 2026
Leo LeeDirector–$14.7MNov 17, 2025
Michael Alexander SmithChief Legal Officer–$9MJun 22, 2026
Melvin Md SharokyDirector–$4.7MAug 17, 2026
David R BrennanDirector–$3.1MSep 9, 2026
Sara BonsteinChief Financial Officer–$2.1MJun 3, 2026
Elizabeth M AndersonDirector–$1MNov 24, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INSM short interest

Moderate short interest. 6.4% of INSM shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14.08M INSM shares were sold short, 6.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 3.96M shares, buying them all back would take about 3.6 trading days (days to cover).

Shares short, % of all shares

6.42%May 15Oct 309.41%

Days to cover

3.6May 15Oct 307.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.08M6.42%+4%3.96M3.6
Oct 15, 202613.48M6.17%-2%3.26M4.1
Sep 30, 202613.80M6.32%+28%2.12M6.5
Sep 15, 202610.80M4.95%-6%2.05M5.3
Aug 31, 202611.44M5.24%+5%1.67M6.9
Aug 14, 202610.89M4.99%-4%4.09M2.7
Jul 31, 202611.35M5.20%-2%2.21M5.1
Jul 15, 202611.62M5.36%-27%2.44M4.8
Jun 30, 202616.03M7.40%-14%5.80M2.8
Jun 15, 202618.65M8.60%-3%4.16M4.5
May 29, 202619.13M8.83%+9%3.13M6.1
May 15, 202617.61M8.12%+20%5.21M3.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded INSM

Since Nov 17, 2024, 2 members of Congress reported 1 purchase and 6 sales of INSM. The latest was a sale by Josh Gottheimer on Jun 10, 2026, reported Jul 7, 2026.

Purchases 1Sales 6

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Jun 10, 2026Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointJul 7, 2026Report
Oct 3, 2025Gilbert Ray Cisneros, Jr. (D-CA)Sale$1K–$15KSelfNov 18, 2025Report
Sep 22, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfOct 10, 2025Report
Aug 8, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfSep 12, 2025Report
Jul 7, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfAug 14, 2025Report
Jun 16, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointJul 16, 2025Report
Apr 9, 2025Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointMay 14, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

INSMED company events

INSMED filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Oct 20, 2026LeadershipThe Board of Directors of Insmed Incorporated appointed Paul Hudson and Utpal Koppikar as members of the Board, effective October 19, 2026. Filing
  3. Oct 5, 2026LeadershipInsmed Incorporated announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 16, 2026AnnouncementShared information with investors. Filing
  6. May 15, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 7, 2026AnnouncementThe Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. The CEDAR study was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brensocatib in adults with moderate to… Filing
  9. Mar 23, 2026AnnouncementThe Company issued a press release announcing positive topline results from the ENCORE Study. Filing
  10. Feb 19, 2026LeadershipDavid W.J. McGirr notified the board of directors of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class II director, which will occur at the Company’s 2026 Annual Meeting of Shareholders. Filing
  11. Jan 9, 2026AnnouncementShared information with investors. Filing
  12. Dec 17, 2025AnnouncementThe Company issued a press release announcing topline efficacy and safety results from the Phase 2b BiRCh study of brensocatib for patients with CRSsNP. The BiRCh study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of… Filing
  13. Nov 18, 2025AnnouncementOn November 18, 2025, the Company announced that the EC has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

INSMED financials

Famous investors that hold INSM

6 of the 50 well-known investors we track reported holding INSM in their latest 13F filing. The largest position is Lee Ainslie's, worth $288M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Lee Ainslie · Maverick CapitalQ3 20262.52M$288M2.3%+17%
Stanley Druckenmiller · Duquesne Family OfficeQ3 20261.09M$125M3.0%-23%
Ken Griffin · Citadel AdvisorsQ3 2026720,688$82.3M0.0%-72%
Jim Simons · Renaissance TechnologiesQ3 2026553,987$63.2M0.1%New
Ray Dalio · Bridgewater AssociatesQ3 2026386,104$44.1M0.2%-15%
Israel Englander · Millennium ManagementQ3 2026349,990$39.9M0.0%-83%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about INSMED Inc (INSM) stock

Who owns the most INSM stock?

The largest reported owner of INSMED Inc (INSM) is FMR LLC (Fidelity), with 7.4% of the company. In total, 662 funds and institutions reported holding INSM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are INSM insiders buying or selling?

In the last 12 months, INSM insiders reported no open-market purchases and 152 sales worth $148M. The latest trade was on Sep 9, 2026. See every trade.

What is the short interest in INSM?

As of Oct 30, 2026, 14.08M INSM shares were sold short, 6.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 3.96M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.

Have members of Congress traded INSM?

Yes. 2 members of Congress reported 1 purchase and 6 sales of INSM since Nov 17, 2024. The latest was reported on Jul 7, 2026. See the trades.

Which famous investors hold INSM?

6 of the 50 well-known investors we track reported INSM in their latest 13F filing, including Lee Ainslie, Stanley Druckenmiller, Ken Griffin. The largest position is worth $288M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.